Literature DB >> 2985195

The regional distribution of receptors for vasoactive intestinal polypeptide (VIP) in the rat central nervous system.

P Staun-Olsen, B Ottesen, S Gammeltoft, J Fahrenkrug.   

Abstract

The regional distribution of receptors for vasoactive intestinal polypeptide (VIP) was studied in the rat central nervous system (CNS). The specific binding was highest in cerebral cortex, limbic forebrain and cerebellum, whereas moderate to low binding was found in hypothalamus, thalamus, brainstem and pituitary. The lowest binding was observed in pons and spinal cord. Scatchard analysis showed curvilinear plots with upward concavity, which was interpreted as two classes of binding sites. The Kd values were similar in all regions and calculated as 2.4 and 62 nmol/liter, respectively. The variations of specific [125I]VIP binding were due to differences in the total amount of receptors and were in the range of 1.7-8.6 pmol per mg protein. The regional distribution of VIP receptors was parallel with the occurrence of VIP-containing nerve terminals with exceptions of cerebellum, olfactory areas and nucleus caudatus, where a greater number of receptors than expected from the VIP content was found. In these regions, VIP may interact with receptors for a different, but homologous neuropeptide. In conclusion, the regional distribution of VIP receptors in CNS gives further evidence for the role of VIP as a central neurotransmitter.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2985195     DOI: 10.1016/0006-8993(85)90691-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  Spatiotemporal distribution of vasoactive intestinal polypeptide receptor 2 in mouse suprachiasmatic nucleus.

Authors:  Sungwon An; Connie Tsai; Julie Ronecker; Alison Bayly; Erik D Herzog
Journal:  J Comp Neurol       Date:  2012-08-15       Impact factor: 3.215

2.  Vasoactive intestinal polypeptide (VIP) containing cells in the developing rat occipital hemisphere.

Authors:  F Hajós; K Zilles; K Gallatz
Journal:  Anat Embryol (Berl)       Date:  1990

3.  Vasoactive intestinal polypeptide excites medial pontine reticular formation neurons in the brainstem rapid eye movement sleep-induction zone.

Authors:  K A Kohlmeier; P B Reiner
Journal:  J Neurosci       Date:  1999-05-15       Impact factor: 6.167

4.  Protective effects of poly (butyl) cyanoacrylate nanoparticles containing vasoactive intestinal peptide against 6-hydroxydopamine-induced neurotoxicity in vitro.

Authors:  Zhi-Ran Xu; Wu-Fang Wang; Xin-Fang Liang; Ze-Hua Liu; Yu Liu; Liang Lin; Xuan Zhu
Journal:  J Mol Neurosci       Date:  2014-10-19       Impact factor: 3.444

5.  Vasoactive intestinal peptide (VIP) treatment of Parkinsonian rats increases thalamic gamma-aminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells.

Authors:  Orhan Tansel Korkmaz; Neşe Tunçel; Muzaffer Tunçel; Elif Mine Oncü; Varol Sahintürk; Mustafa Celik
Journal:  J Mol Neurosci       Date:  2009-12-02       Impact factor: 3.444

6.  Ramification patterns of vasoactive intestinal polypeptide (VIP)-cells in the rat primary visual cortex. An immunohistochemical study.

Authors:  F Hajós; K Zilles; K Gallatz; A Schleicher; I Kaplan; L Werner
Journal:  Anat Embryol (Berl)       Date:  1988

7.  Quantitative immunohistochemical analysis of VIP-neurons in the rat visual cortex.

Authors:  F Hajós; K Zilles
Journal:  Histochemistry       Date:  1988

8.  Vasoactive intestinal polypeptide immunoreactivity in the human cerebellum: qualitative and quantitative analyses.

Authors:  Vincenzo Benagiano; Paolo Flace; Loredana Lorusso; Anna Rizzi; Lorenzo Bosco; Raffaele Cagiano; Glauco Ambrosi
Journal:  J Anat       Date:  2009-06-22       Impact factor: 2.610

9.  Neuronal number and volume alterations in the neocortex of HIV infected individuals.

Authors:  I P Everall; P J Luthert; P L Lantos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-05       Impact factor: 10.154

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.